<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909593</url>
  </required_header>
  <id_info>
    <org_study_id>A4091</org_study_id>
    <nct_id>NCT04909593</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial</brief_title>
  <acronym>AIM</acronym>
  <official_title>Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial: The AIM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the feasibility of using information extracted from&#xD;
      physiologic signals to automatically adjust stimulation in patients undergoing Spinal Cord&#xD;
      Stimulation (SCS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perception Threshold</measure>
    <time_frame>up to 15 days post-screening</time_frame>
    <description>Percent change in perception threshold from sitting to standing</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Intractable Pain</condition>
  <condition>Low Back Pain</condition>
  <condition>Pain, Neuropathic</condition>
  <condition>Pain, Back</condition>
  <arm_group>
    <arm_group_label>Spinal Cord Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCS trial systems including external trial stimulators, lead(s)/extensions(s), and operating room (OR) cable(s)/extender(s) and optional sensor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spinal Cord Stimulation</intervention_name>
    <description>Spinal cord stimulation at varied electrode, pulse width, frequency and amplitude parameters</description>
    <arm_group_label>Spinal Cord Stimulation</arm_group_label>
    <other_name>neurostimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Study candidate is undergoing a temporary SCS trial of commercially approved BSC&#xD;
             neurostimulator system, per local directions for use (DFU).&#xD;
&#xD;
          -  Subject signed a valid, EC/IRB-approved informed consent form.&#xD;
&#xD;
          -  Age 18 or above, or above legal age and willing and capable of giving informed consent&#xD;
             specific to national law when written informed consent is obtained.&#xD;
&#xD;
          -  In the clinician best judgment, subject is able to distinguishably describe quality&#xD;
             and location of sensation and pain.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Subject meets any contraindication in BSC neurostimulation system local DFU.&#xD;
&#xD;
          -  Investigator-suspected gross lead migration during the SCS trial period which may&#xD;
             preclude the study candidate from receiving adequate SCS therapy.&#xD;
&#xD;
          -  Subject is currently diagnosed with cognitive impairment, or exhibits any&#xD;
             characteristic, that in the clinician's best judgement would limit study candidate's&#xD;
             ability to assess and report sensation information.&#xD;
&#xD;
          -  Subject is currently diagnosed with a physical impairment, or exhibits a condition&#xD;
             that would limit study candidate's ability to complete study assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen Lechleiter, M.S.</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Neuromodulation Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen Lechleiter, M.S.</last_name>
    <phone>855-213-9890</phone>
    <email>BSNClinicalTrials@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heleen Scholtes</last_name>
    <phone>855-213-9890</phone>
    <email>BSNClinicalTrials@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PCPMG Clinical Research Unit, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boston Scientific Clinical Research Manager</last_name>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </contact>
    <investigator>
      <last_name>Eric P Loudermilk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Pain, Intractable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

